Spatial learning deficit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau filaments

Journal of Neurochemistry

Volumn 83, Issue 6, 2002, Pages 1529-1533

  Hernández, Félix ^a   Borrell, José ^b   Guaza, Carmen ^b   Avila, Jesús ^a   Lucas, José J ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b INSTITUTO CAJAL   (Spain)

Author keywords

Alzheimer's disease; GSK 3; Spatial learning; Tau; Transgenic mice

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; GENE OVEREXPRESSION; HIPPOCAMPUS; LEARNING DISORDER; MEASUREMENT; MICROTUBULE; MOUSE; NERVE CELL; NERVE CELL NECROSIS; NEUROFILAMENT; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; ENZYME ACTIVATION; GLYCOGEN SYNTHASE KINASE 3; IMMUNOHISTOCHEMISTRY; LEARNING DISORDERS; MACROMOLECULAR SUBSTANCES; MALE; MAZE LEARNING; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; SPATIAL BEHAVIOR; TAU PROTEINS;

ANIMALIA; MUS MUSCULUS;

EID: 1642363745     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2002.01269.x     Document Type: Article

References (27)

1. Alvarez G., Munoz-Montano J. R., Satrustegui J., Avila J., Bogonez E. and Diaz-Nido J. (1999) Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett. 453, 260-264.
2. Cross D. A., Culbert A. A., Chalmers K. A., Facci L., Skaper S. D. and Reith A. D. (2001) Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. 77, 94-102.
3. Eldar-Finkelman H. (2002) Glycogen synthase kinase 3: An emerging therapeutic target. Trends Mol. Med. 8, 126-132.
4. Gotz J., Chen F., van Dorpe J. and Nitsch R. M. (2001) Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491-1495.
5. Grimes C. A. and Jope R. S. (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 65, 391-426.
6. Hong M., Chen D. C., Klein P. S. and Lee V. M. (1997) Lithium reduces tau phosphorylafion by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 272, 25326-25332.
7. Imahori K. and Uchida T. (1997) Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J. Biochem. (Tokyo) 121, 179-188.
8. Lewis J., Dickson D. W., Lin W. L., Chisholm L., Corral A., Jones G., Yen S. H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M. and McGowan E. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491.
9. Lim F., Hernandez F., Lucas J. J., Gomez-Ramos P., Moran M. A. and Avila J. (2001) FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol. Cell Neurosci. 18, 702-714.
10. Lovestone S., Reynolds C. H., Latimer D., Davis D. R., Anderton B. H., Gallo J. M., Hanger D., Mulot S., Marquardt B., Stabel S., Woodgett J. R. and Miller C. C. J. (1994) Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 4, 1077-1086.
11. Lucas J. J., Hernandez F. and Avila J. (1999) Nuclear localization of beta-catenin in adult mouse thalamus correlates with low levels of GSK-3beta. Neuroreport 10, 2699-2703.
12. Lucas J. J., Hernandez F., Gomez-Ramos P., Moran M. A., Hen R. and Avila J. (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20, 27-39.
13. Martin-Aparicio E., Yamamoto A., Hernandez F., Hen R., Avila J. and Lucas J. J. (2001) Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J. Neurosci. 21, 8772-8781.
14. Martinez A., Alonso M., Castro A., Perez C. and Moreno F. J. (2002a) First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 45, 1292-1299.
15. Martinez A., Castro A., Dorronsoro I. and Alonso M. (2002b) Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 22, 373-384.
16. Moreno F. J., Munoz-Montano J. R. and Avila J. (1996) Glycogen synthase kinase 3 phosphorylation of different residues in the presence of different factors: Analysis on tau protein. Mol. Cell. Biochem. 165, 47-54.
17. Munoz-Montano J. R., Moreno F. J., Avila J. and Diaz-Nido J. (1997) Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411, 183-188.
18. Pei J. J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B. and Cowburn R. F. (1999) Distribution of active glycogen synthase kinase-3 beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58, 1010-1019.
19. Perez M., Valpuesta J. M., de Garcini E. M., Quintana C., Arrasate M., Lopez Carrascosa J. L., Rabano A., Garcia de Yebenes J. and Avila J. (1998) Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy. Am. J. Pathol 152, 1531-1539.
20. Price D. L., Sisodia S. S. and Borchelt D. R. (1998) Genetic neurodegenerative diseases: The human illness and transgenic models. Science 282, 1079-1083.
21. Rapoport M., Dawson H. N., Binder L. I., Vitek M. P. and Ferreira A. (2002) Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA 99, 6364-6369.
22. Stambolic V. and Woodgett J. R. (1994) Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem. J. 303, 701-704.
23. Takashima A., Noguchi K., Sato K., Hoshino T. and Imahori K. (1993) Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc. Natl. Acad. Sci. USA 90, 7789-7793.
24. Takashima A., Noguchi K., Michel G., Mercken M., Hoshi M., Ishiguro K. and Imahori K. (1996) Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci. Lett. 203, 33-36.
25. Tobin A. J. and Signer E. R. (2000) Huntington's disease: The challenge for cell biologists. Trends Cell Biol. 10, 531-536.
26. Yamaguchi H., Ishiguro K., Uchida T., Takashima A., Lemere C. A. and Imahori K. (1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. (Berl) 92, 232-241.
27. Yamamoto A., Lucas J. J. and Hen R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66.